Issues
-
Cover Image
Cover Image
Immunometabolism is emerging as a critical determinant of cancer pathophysiology. A balance between tumor promotion and elimination is dependent on the state of functional polarization of macrophage populations within the tumor microenvironment. Lactic acid generated by lactate dehydrogenase-A is a key metabolite that facilities the immunosuppressive tumor microenvironment. Deletion of lactate dehydrogenase-A in myeloid cells restores the immunocompetent tumor microenvironment by reversing macrophage phenotype and antitumor immunity. Immunofluorescence staining revealed an increased number of infiltrating inducible nitric oxide synthase-positive (red) and M1-skewed F4.80-positive (green) macrophages in K-Ras tumors after deletion of lactate dehydrogenase-A. For details, see article by Seth and colleagues on page 3632. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Advances
Obituary
Meeting Report
Obstacles, Opportunities and Priorities for Advancing Metastatic Breast Cancer Research
Molecular and Cellular Pathobiology
Cyclin D1 Restrains Oncogene-Induced Autophagy by Regulating the AMPK–LKB1 Signaling Axis
Tumor and Stem Cell Biology
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer
Liver Metastasis Is Facilitated by the Adherence of Circulating Tumor Cells to Vascular Fibronectin Deposits
Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer
Therapeutics, Targets, and Chemical Biology
Targetable T-type Calcium Channels Drive Glioblastoma
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer
Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity
Microenvironment and Immunology
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy
Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling
Prevention and Epidemiology
Retraction
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.